Advisors Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Advisors Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.89M	Sell	123,743 -53,960	-30%	-$1.59M	0.06%	422
2026 Q1	$4.4M	Sell	177,703 -1,464	-0.8%	-$34.9K	0.07%	364
2025 Q4	$4.18M	Sell	179,167 -13,481	-7%	-$300K	0.07%	370
2025 Q3	$3.8M	Buy	192,648 +1,132	+0.6%	+$23.3K	0.06%	403
2025 Q2	$4.16M	Buy	191,516 +12,650	+7%	+$299K	0.07%	357
2025 Q1	$4.34M	Buy	178,866 +12,819	+8%	+$289K	0.08%	321
2024 Q4	$3.47M	Sell	166,047 -11,286	-6%	-$242K	0.06%	411
2024 Q3	$3.53M	Buy	177,333 +11,484	+7%	+$213K	0.06%	397
2024 Q2	$2.57M	Sell	165,849 -59,226	-26%	-$922K	0.05%	471
2024 Q1	$3.59M	Buy	225,075 +24,575	+12%	+$370K	0.07%	354
2023 Q4	$3.37M	Sell	200,500 -118,480	-37%	-$1.62M	0.07%	358
2023 Q3	$3.73M	Sell	318,980 -3,374	-1%	-$45.1K	0.08%	317
2023 Q2	$4.33M	Buy	322,354 +3,606	+1%	+$51.9K	0.09%	284
2023 Q1	$5.28M	Buy	318,748 +905	+0.3%	+$14.9K	0.11%	231
2022 Q4	$5.91M	Buy	317,843 +66,650	+27%	+$1.03M	0.12%	188
2022 Q3	$3.22M	Buy	251,193 +2,671	+1%	+$31.7K	0.06%	342
2022 Q2	$1.74M	Buy	248,522 +113,743	+84%	+$834K	0.03%	563
2022 Q1	$1.12M	Buy	134,779 +90,820	+207%	+$642K	0.02%	771
2021 Q4	$298K	Buy	+43,959	New	+$289K	﹤0.01%	1138

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisors Asset Management's CPRX Position: Q2 2026 in Review

Advisors Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 30% in Q2 2026, selling an estimated $1.59M and leaving 123,743 shares worth $3.89M. The position accounts for 0.06% of the portfolio, ranked #422.

Advisors Asset Management first reported a position in CPRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $5.91M in Q4 2022. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Advisors Asset Management held 123,743 shares of Catalyst Pharmaceutical worth $3.89M as of Q2 2026.
Advisors Asset Management sold 53,960 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.59M.
Catalyst Pharmaceutical made up 0.06% of Advisors Asset Management's portfolio in Q2 2026, its #422 holding.
Advisors Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 19 quarters since.
Advisors Asset Management's Catalyst Pharmaceutical position peaked at $5.91M in Q4 2022.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.